We could announce an $8 billion share buy back and this stock wouldn't move
Like watching paint dry IMHO
MARIETTA, Ga., Nov. 26, 2013 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the summaries of a selection of the seven posters highlighting MiMedx allografts presented at the recent 10th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona.
The posters chronicled the clinical effectiveness of the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts and detailed a wide range of wounds and injuries with varying degrees of etiologies. A sampling of the posters presenting dHACM cases and studies, along with a summary of the respective study results and conclusions are as follows:
•EpiFix Utilization for Advanced Wound Therapy in an Evidence Based Approach to Treat Foot Ulcers.•Results: 10 non-healing diabetic foot ulcers (DFUs) and 3 pressure ulcers were treated with EpiFix®. 75% of the ulcers healed with EpiFix® at an average healing time of 11.7 weeks after 3.5 applications. Complete healing occurred in 67% of the DFUs and 100% of pressure ulcers. Of the 3 DFUs not healing 100%, 2 were non-compliant and one had foot deformity issues prior to the study causing discontinuation of the graft.
•Conclusion: Multiple advantages were noted in using EpiFix® to treat non-healing wounds in the VA clinic setting including ease of use and availability of multiple graft sizes to minimize waste. With adequate wound debridement and proper wound bed maintenance, a 75% healing rate of non-healing foot ulcers was achieved with the utilization of EpiFix®.
•Dehydrated Human Amnion/Chorion Membrane for the Treatment of Full-Thickness Plantar Burn in a Diabetic Patient: A Case Report.•Results: Rapid healing of wound occurred with epithelialization essentially complete 4 weeks after dHACM application.
•Conclusion: This case report demonstrated that dHACM can be used as an effective treatment for plantar burns in diabetics and deserves further study.
•Treatment of Lower Extremity Chronic Wounds with Dehydrated Human Amnion/Chorion Membrane (dHACM): A Vascular Compromised Cohort (ABI
No shocker here but this stock is being wildly manipulated. this is a real deterrent for any new shareholders looking to invest in our company IMO
technically we have reseted 3 days at unch on higher volume
Tonight some bozo tried to paint the tape with 800 shares to sell at 5.90
I hope that Pete, Bill T, Mike S et al have a plan to get these parasites exterminated once and for all.
A faithful long term shareholder
another 70k shares covered over the last 2 weeks of October
Days to cover still super high at over 11
10/31/2013 7,329,530 649,511 11.284690
10/15/2013 7,399,910 405,460 18.250654
nice call however one thing you did not spot was ..."The FDA acknowledged that our presentation included new information that they would review and consider, and they committed to responding in a timely fashion".
Clearly the FDA did not do it's job and MDXG had to educate them.
I see comments from the FDA within the next week and additionally positive color from management on the cc tomorrow. JMHO
From the last conf call -------
Outlook for Third Quarter and Full Year 2013
The Company reaffirmed its previously communicated guidance for full year 2013, but increased the lower end of the range. 2013 full year revenue is forecasted to be in the range of $54 million to $60 million. The Company's goals for the third quarter of 2013 are for revenue to be in the range of $13.5 million to $16.0 million. The point within the range of revenue goals largely will be dependent on whether and how quickly the remaining MACs begin to reimburse for the Company's EpiFix® allografts.
Now if the company has guided over 16mill this quarter how might they achieve this?
I agree to a point
one has to believe this really set Pete off. although he is human he is a very driven personality ... just thinking back to Matria and MDXG etc.
I will say again I expect good news to come from all this and MDXG, Pete et al will be very proactive about reporting the result
FDA meeting is the 16th
Knowing managements experience this is not their first rodeo
I expect they will have a very thorough presentation to the FDA - not to mention the fact other companies are already using the same process
One may recall Petit had to deal with similar stupidity when he was at Matria
Why MDXG was singled out (I get leadership position) when others are using the same process will correct itself.
I see JPM being the next company to upgrade time will tell
Todays trading is technical as we failed to hold the 50 DMA ... not fundamental IMO
Poster on MiMedx EpiFix® Receives Highest Score at the Symposium on Advanced Wound Care (SAWC)
EpiFix® is the subject of six poster abstracts accepted at SAWC 10/03 04:07 PM
MARIETTA, Ga., Oct. 3, 2013 /PRNewswire/ -- MiMedx Group (MDXG:$4.53,00$0.07,001.57%) , Inc. , an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that a poster detailing an EpiFix® case study received the award for the highest scoring abstract in the case study category at the recent Symposium on Advanced Wound Care ("SAWC"). In all, six posters chronicling the clinical effectiveness of EpiFix® were accepted for presentation at the recent SAWC.
The abstract titledA Long-term Follow-up Study of Chronic Diabetic Foot Ulcers Healed with Dehydrated Human Amniotic/Chorionic Membrane Allografts was recognized at the SAWC as the highest scoring poster abstract in the Case Study category. The authors honored at the SAWC for the winning abstract were Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS; and Donald E. Fetterolf, MD, MBA, FACP.
The five other posters presenting EpiFix® cases and studies were:
Clinical and Cost Effectiveness of Dehydrated Human Amniotic/Chorionic Membrane Allografts for the Treatment of Non-Healing Wounds.
Dehydrated Human Amniotic Membrane for the Treatment of Pressure Ulcers in Spinal Cord Injured Veterans: A Case Series.
Dehydrated Human Amnion/Chorion Membrane Tissue Graft for the Treatment of Intractable Ulceration: A Series of Extraordinary Outliers.
Use of Dehydrated Human Amniotic Membrane Allografts to Promote Healing in Patients with Refractory Non-Healing Wounds.
Viable Indications for the Use of Human Amniotic Membrane Allograft: A Case Series.
The six poster abstracts presented results of treatment with EpiFix® for a wide range of applications, including the treatment of non-healing wounds, pressure ulcers in spinal cord injured veterans, diabetic foot ulcers and intractable ulceration. The poster abstracts presented case and study results that showed closure of multiple different types of non-healing wounds using EpiFix®. In one poster abstract comparing EpiFix® with a competitor's human fibroblast derived dermal substitute, the study cases demonstrated an 82% reduction in cost of wound closure in non-healing wounds treated with EpiFix®. In another poster abstract, the case study examined the use of EpiFix® for the treatment of difficult intractable wounds and concluded that difficult wounds which did not heal after treatment with a payer approved amount of bioengineered skin substitute, even those wounds secondary to radiation, responded and healed with EpiFix® treatment.
Parker H. "Pete" Petit, Chairman and CEO, said "In general, the abstracts accepted for presentation at the SAWC cited the use of EpiFix® for treatment of wounds that previously were treated with commercially available living cell skin substitutes without wound closure and healing, but had successful healing and closure with EpiFix®."
Each year, the SAWC recognizes the highest scoring poster abstracts in four categories: Case Study, Clinical Research, Informational/Educational Report, and Laboratory Research. The winning poster presented a case series following up on the rates of recurrence of chronic DFUs after previous healing with use of EpiFix®. Evaluation of clinical records was made with IRB approval and patient consent. Eighteen of 22 eligible patients returned for follow-up examination, which was conducted 9 – 12 months after original healing with EpiFix®. Only one patient had recurrent DFU during the follow-up period, while 17, or 94.4%, remained fully healed. These findings support the long-term effectiveness of dehydrated human amnion/chorion membrane ("dHACM") for treatment of DFU. The study concluded that dHACM is a clinically viable and economically feasible treatment option that should be considered by clinicians who treat diabetic pedal ulcers.
Petit added, "We are pleased that an abstract identifying the impressive healing properties of our EpiFix® allograft received this top recognition. The identification and implementation of an ideal treatment regimen for diabetic foot ulcers (DFUs) is an increasingly common issue faced by clinicians. Therapies that promote rapid and complete healing, thus reducing the risk for infection and amputation, can substantially improve quality of life while decreasing financial burdens. We believe our EpiFix® allograft is a clinically effective and economic solution to these needs."
Bill Taylor, President and COO, stated, "Human amniotic membrane has been used as an allograft to treat wounds for over a century. However, our proprietary PURION® process has led to the development of our EpiFix® dHACM allograft. Studies have shown strong clinical and cost effectiveness of EpiFix® for healing of DFUs, pressure ulcers, and wounds that have failed to heal with other treatment modalities with minimal, if any, waste. Use of competitive skin substitutes routinely result in waste of over 75% of their graft because they come in only one very large size, which is generally at least 15 times greater than the average DFU. EpiFix® has size appropriate grafts and does not waste such material."